Physician profile
Robert Jay Sipzner
NPI 1467491589
$5,310.21
in general payments reported to CMS, 2019-2025
33 companies · $947 in 2025
The $947 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $241 · 2021: $626 · 2022: $890 · 2023: $1,400 · 2024: $859 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,131 · Education: $75.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,130.60 |
| Education | $75.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,065.38 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $948.62 | 2019-2025 | Repatha, Krystexxa, Tavneos |
| Vifor Pharma, INC. | $458.61 | 2019-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $388.81 | 2021-2025 | |
| Novo Nordisk INC | $270.96 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Travere Therapeutics, INC. | $228.20 | 2024-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $212.01 | 2019-2025 | Jynarque |
| Abbvie INC. | $210.20 | 2021-2025 | Ubrelvy |
| Opko Pharmaceuticals, LLC | $191.35 | 2021-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $149.38 | 2022-2024 | Benlysta, Jesduvroq |
| Ardelyx, INC. | $142.53 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $140.47 | 2021-2025 | Acthar |
| Calliditas Therapeutics US INC. | $123.89 | 2022-2025 | Tarpeyo |
| Arbor Pharmaceuticals, INC. | $122.37 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $99.11 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $85.42 | 2023 | |
| Lilly USA, LLC | $82.88 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $48.89 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Horizon Therapeutics Plc | $43.33 | 2019-2022 | |
| Akebia Therapeutics INC | $40.34 | 2024-2025 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.73 | 2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $27.85 | 2019-2024 | Evkeeza |
| Hikma Pharmaceuticals USA | $27.12 | 2019-2021 | |
| Amarin Pharma, INC. | $25.59 | 2019-2021 | |
| Eisai INC. | $23.01 | 2021 | |
| Aurinia Pharma U.S., INC. | $19.07 | 2025 | Lupkynis |
| Scpharmaceuticals INC. | $17.89 | 2025 | |
| Nevro Corp. | $16.82 | 2021 | |
| Esperion Therapeutics, INC. | $15.41 | 2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $15.16 | 2023 | Gattex |
| Avion Pharmaceuticals | $14.10 | 2020 | |
| Daiichi Sankyo INC. | $12.75 | 2019 | |
| Althera Pharmaceuticals LLC | $8.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sipzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.